The quality of life of lung cancer patients is affected by several factors
related to the patients, stage of disease and treatment characteristics. Fo
r small-cell lung cancer (SCLC), the treatment is generally aggressive, pri
marily based on chemotherapy. Treatment strategy for non-small-cell lung ca
ncer (NSCLC) is strongly dependent on the stage of the disease and ranges f
rom surgery to palliative chemotherapy. Over the last few years, very littl
e progress has been made in terms of survival. Therefore, the effect of tre
atment on quality of life has become progressively more relevant. Among the
instruments for measuring quality of life, there are some specifically dev
eloped for lung cancer, such as the European Organization for Research and
Treatment of Cancer (EORTC) LC-13 questionnaire, the Functional Assessment
of Cancer Therapy (FACT-L) questionnaire and the Lung Cancer Symptom Scale
(LCSS). Up to now, few randomised clinical trials have correctly evaluated
quality of life. There are evident pitfalls associated with the use of freq
uently non-validated tools, and poor methods of data analysis, but quality-
of-life evaluation is crucial and should be addressed through well-planned
and well-conducted prospective clinical trials.